You are here: Industry Insights > Market News > Granules India gets board nod to raise foreign investment limit

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

Hot Products

Propantheline Bromide

carbomer 974P

Coenzyme Q10

Refined Fish Oil

Black Currant Extract

Hydrocortisone

Granules India gets board nod to raise foreign investment limit

financialexpressJuly 06, 2017

Tag: granules , foreign investment

Favorites

Granules India said its board has approved a proposal to increase the foreign investment limit in the company to 49 per cent.

The board of directors has agreed to increase the present limit of FII/ FPIs shareholding in the company to 49 per cent of the total paid-up equity share capital, Granules India said in a BSE filing.

However, it said, the decision would be subject to shareholders’ approval.

As on March 31, 2017, FPI holding in the company stood at 9.98 per cent. Other foreign nationals owned 0.06 per cent.

Previous:Zydus starts phase II trial of ZYAN1 for treating anaemia in patients with CKD

Next:Pain-free microneedle patch could help boost flu vaccination rates

Data of InnoCare’s Robust Pipelines Presented at the European Hematology Association (EHA) 2024 Hybrid Congress

PharmaSourcesJune 14, 2024

Data of InnoCare’s (HKEX: 09969; SSE: 688428) robust pipelines were presented at the European Hematology Association (EHA) 2024 Hybrid Congress.

InnoCare Announces Clearance of Clinical Trial of TYK2 Inhibitor ICP-332 by U.S. FDA

PharmaSourcesJune 11, 2024

HighTide Therapeutics Presents Analyses of Phase 2a MASH Study at the 2024 International Liver Congress

PharmaSourcesJune 05, 2024

Granules India gets board nod to raise foreign investment limit | Pharmasources.com

New Research Launched at BIO24 Finds CROs with In-house Regulatory Affairs Can Deliver 30% Savings, Halve Timelines and Cut Risks for Biotechs

PharmaSourcesJune 05, 2024

New research showes that biotechs can save more than 30% in costs, halve start-up times, and cut risk with CROs that have in-house scientific and regulatory affairs.

Granules India gets board nod to raise foreign investment limit

Related News

Data of InnoCare’s Robust Pipelines Presented at the European Hematology Association (EHA) 2024 Hybrid Congress

InnoCare Announces Clearance of Clinical Trial of TYK2 Inhibitor ICP-332 by U.S. FDA

HighTide Therapeutics Presents Analyses of Phase 2a MASH Study at the 2024 International Liver Congress

New Research Launched at BIO24 Finds CROs with In-house Regulatory Affairs Can Deliver 30% Savings, Halve Timelines and Cut Risks for Biotechs

You may like